DRUG TRIAL
aussie59
Member Posts: 48
Hi Everyone I came across another drug trial today as follows
We will beat this disease one day. Irene
Women with recurrent ovarian cancer can be helped by an experimental therapy using a drug already touted for its ability to fight other cancers, a finding that provides hope for improved treatment of this deadly disease.
Dr. Bradley Monk, a UC Irvine gynecologic oncologist who led the worldwide phase III clinical trial, said trabectedin is the most recent addition to a short list of active drug therapies for recurrent ovarian cancer. He presents study results Sept. 15 at the 33rd Congress of the European Society for Medical Oncology in Stockholm.
"These are exciting results because positive trials in recurrent ovarian cancer are rare and have almost always led to federally approved treatments," said Monk, an associate professor who studies and treats ovarian cancers at the Chao Family Comprehensive Cancer Center at UC Irvine. "This treatment undoubtedly will be evaluated carefully by the U.S. Food and Drug Administration and, if approved, will give women with ovarian cancer another much needed option."
Phase III studies are multicenter trials on large patient groups designed to be the definitive assessment of a drug's effectiveness. Such a study is often the last step before a drug is reviewed by a regulatory agency like the FDA for approval as a safe, effective treatment.
In this trial, an international group of researchers treated 672 women whose ovarian cancer had progressed after first-line treatment. Half the women received a combination therapy of trabectedin and a chemotherapy drug called pegylated liposomal doxorubicin. The other half received the chemotherapy drug alone, which is standard treatment in these cases.
In patients on the combination therapy, researchers found no progression of the cancer for an average of 7.3 months, as compared to 5.8 months for those treated with the single drug. For those who had relapsed more than six months after the first-line therapy, the median progression-free time was 9.2 months for the combination treatment, as compared to 7.5 months for the other patients.
Under the brand name Yondelis, trabectedin is approved in Europe and South Korea for treating advanced soft tissue sarcoma. In addition to the phase III ovarian cancer trial, it is being studied in smaller, phase II trials for prostate, breast and pediatric cancers.
Trabectedin is a synthetic version of a compound isolated from the sea squirt, a tubular sea animal used in a number of medical studies. It binds to the DNA of a cancer cell and blocks its ability to multiply, thus killing the cells and shrinking tumors.
When ovarian cancer is detected early - when it is confined to the ovaries - more than 90 percent of women will live at least five years, according to the American Cancer Society. Only about 20 percent of cases are detected that early. If the cancer is detected after it has spread, only about 30 percent of women survive five years. Each year, approximately 20,000 American women are diagnosed with ovarian cancer and about 15,000 die of the disease.
http://www.uci.edu/
An investigational drug that combats ovarian cancer by inhibiting the formation of new blood vessels has shown promise in a phase II trial, according to a presentation at the 33rd Congress of the European Society for Medical Oncology (ESMO) in Stockholm.
Prof. Michael Friedlander from Australia presented the results of an international collaborative trial which administered the drug to 35 patients with recurrent ovarian, fallopian tube or peritoneal carcinoma. At the ESMO Congress, he presented final results of the trial on behalf of his co-investigators.
Women who had already been treated with one or two previous chemotherapy regimens were eligible for the study provided they only had an elevated CA-125 or small tumors on scans. Each participant received 800mg of the oral drug daily, and the primary outcome measure was a decrease in blood levels of the protein CA-125.
CA-125 is a biological marker used to predict tumor recurrence and response to chemotherapy. Levels of the protein rise on average about 3 months before onset of symptoms or scan evidence of recurrence. Hence, it is an attractive marker to assess the efficacy of new agents such as pazopanib when the tumor volume is low.
The study showed that 31% of the patients had a greater than 50% decrease in CA-125 levels, with median duration of response at 113 days, Prof. Friedlander said. It was generally well tolerated, with a similar spectrum of side-effects seen with other angiogenesis inhibitors.
"Many patients with ovarian cancer will have a recurrence of cancer following initial chemotherapy," he said. "This study clearly demonstrates that pazopanib is an active, well-tolerated drug for women with recurrent ovarian cancer."
The findings of this study support further investigation of the potential role of pazopanib in the management of women with ovarian cancer, Prof. Friedlander added. An international phase III study investigating the drug for ovarian cancer will now go ahead.
"The majority of patients with ovarian cancer will have advanced disease at the time of initial diagnosis," Prof. Friedlander said. "Typically, these patients are managed with surgery followed by combination chemotherapy. Unfortunately most patients will relapse usually within 2 years following the initial therapy. There is therefore a real need to investigate novel agents such as pazopanib to ensure new therapeutic options for patients with ovarian cancer."
http://www.esmo.org/
We will beat this disease one day. Irene
Women with recurrent ovarian cancer can be helped by an experimental therapy using a drug already touted for its ability to fight other cancers, a finding that provides hope for improved treatment of this deadly disease.
Dr. Bradley Monk, a UC Irvine gynecologic oncologist who led the worldwide phase III clinical trial, said trabectedin is the most recent addition to a short list of active drug therapies for recurrent ovarian cancer. He presents study results Sept. 15 at the 33rd Congress of the European Society for Medical Oncology in Stockholm.
"These are exciting results because positive trials in recurrent ovarian cancer are rare and have almost always led to federally approved treatments," said Monk, an associate professor who studies and treats ovarian cancers at the Chao Family Comprehensive Cancer Center at UC Irvine. "This treatment undoubtedly will be evaluated carefully by the U.S. Food and Drug Administration and, if approved, will give women with ovarian cancer another much needed option."
Phase III studies are multicenter trials on large patient groups designed to be the definitive assessment of a drug's effectiveness. Such a study is often the last step before a drug is reviewed by a regulatory agency like the FDA for approval as a safe, effective treatment.
In this trial, an international group of researchers treated 672 women whose ovarian cancer had progressed after first-line treatment. Half the women received a combination therapy of trabectedin and a chemotherapy drug called pegylated liposomal doxorubicin. The other half received the chemotherapy drug alone, which is standard treatment in these cases.
In patients on the combination therapy, researchers found no progression of the cancer for an average of 7.3 months, as compared to 5.8 months for those treated with the single drug. For those who had relapsed more than six months after the first-line therapy, the median progression-free time was 9.2 months for the combination treatment, as compared to 7.5 months for the other patients.
Under the brand name Yondelis, trabectedin is approved in Europe and South Korea for treating advanced soft tissue sarcoma. In addition to the phase III ovarian cancer trial, it is being studied in smaller, phase II trials for prostate, breast and pediatric cancers.
Trabectedin is a synthetic version of a compound isolated from the sea squirt, a tubular sea animal used in a number of medical studies. It binds to the DNA of a cancer cell and blocks its ability to multiply, thus killing the cells and shrinking tumors.
When ovarian cancer is detected early - when it is confined to the ovaries - more than 90 percent of women will live at least five years, according to the American Cancer Society. Only about 20 percent of cases are detected that early. If the cancer is detected after it has spread, only about 30 percent of women survive five years. Each year, approximately 20,000 American women are diagnosed with ovarian cancer and about 15,000 die of the disease.
http://www.uci.edu/
An investigational drug that combats ovarian cancer by inhibiting the formation of new blood vessels has shown promise in a phase II trial, according to a presentation at the 33rd Congress of the European Society for Medical Oncology (ESMO) in Stockholm.
Prof. Michael Friedlander from Australia presented the results of an international collaborative trial which administered the drug to 35 patients with recurrent ovarian, fallopian tube or peritoneal carcinoma. At the ESMO Congress, he presented final results of the trial on behalf of his co-investigators.
Women who had already been treated with one or two previous chemotherapy regimens were eligible for the study provided they only had an elevated CA-125 or small tumors on scans. Each participant received 800mg of the oral drug daily, and the primary outcome measure was a decrease in blood levels of the protein CA-125.
CA-125 is a biological marker used to predict tumor recurrence and response to chemotherapy. Levels of the protein rise on average about 3 months before onset of symptoms or scan evidence of recurrence. Hence, it is an attractive marker to assess the efficacy of new agents such as pazopanib when the tumor volume is low.
The study showed that 31% of the patients had a greater than 50% decrease in CA-125 levels, with median duration of response at 113 days, Prof. Friedlander said. It was generally well tolerated, with a similar spectrum of side-effects seen with other angiogenesis inhibitors.
"Many patients with ovarian cancer will have a recurrence of cancer following initial chemotherapy," he said. "This study clearly demonstrates that pazopanib is an active, well-tolerated drug for women with recurrent ovarian cancer."
The findings of this study support further investigation of the potential role of pazopanib in the management of women with ovarian cancer, Prof. Friedlander added. An international phase III study investigating the drug for ovarian cancer will now go ahead.
"The majority of patients with ovarian cancer will have advanced disease at the time of initial diagnosis," Prof. Friedlander said. "Typically, these patients are managed with surgery followed by combination chemotherapy. Unfortunately most patients will relapse usually within 2 years following the initial therapy. There is therefore a real need to investigate novel agents such as pazopanib to ensure new therapeutic options for patients with ovarian cancer."
http://www.esmo.org/
0
Comments
Discussion Boards
- All Discussion Boards
- 6 CSN Information
- 6 Welcome to CSN
- 121.9K Cancer specific
- 2.8K Anal Cancer
- 446 Bladder Cancer
- 309 Bone Cancers
- 1.6K Brain Cancer
- 28.5K Breast Cancer
- 398 Childhood Cancers
- 27.9K Colorectal Cancer
- 4.6K Esophageal Cancer
- 1.2K Gynecological Cancers (other than ovarian and uterine)
- 13K Head and Neck Cancer
- 6.4K Kidney Cancer
- 671 Leukemia
- 793 Liver Cancer
- 4.1K Lung Cancer
- 5.1K Lymphoma (Hodgkin and Non-Hodgkin)
- 237 Multiple Myeloma
- 7.1K Ovarian Cancer
- 61 Pancreatic Cancer
- 487 Peritoneal Cancer
- 5.5K Prostate Cancer
- 1.2K Rare and Other Cancers
- 540 Sarcoma
- 731 Skin Cancer
- 653 Stomach Cancer
- 191 Testicular Cancer
- 1.5K Thyroid Cancer
- 5.8K Uterine/Endometrial Cancer
- 6.3K Lifestyle Discussion Boards